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The concerted action of proteolytic enzymes that either promote or
directly take part in extracellular matrix (ECM) and basement
membrane (BM) degradation and remodelling is considered of
main importance in cancer invasion and metastatic spread
(Bernstein and Liotta, 1994). These proteinases are excreted by
different cells like macrophages, fibroblasts, normal or malignant
epithelial cells as inactive pro-enzymes, zymogens. Their function
is regulated by other proteinases, growth-factors and specific
inhibitors. Cathepsin D (cath-D) and urokinase plasminogen acti-
vator (uPA) are the two most widely studied proteolytic enzymes
in breast cancer research.
Cathepsin D is an aspartic lysosomal proteinase that is active in
acidic pH. Cell culture studies suggest that cath-D may be active in
carcinomas either as a proteolytic enzyme or a mitogen (Westley
and May, 1996). Since 1989 the independent adverse prognostic
sign of high cath-D concentrations of tissue extracts in breast
cancer has been demonstrated in numerous studies (Thorpe et al,
1989; Duffy et al, 1991, 1992; Kute et al, 1991; Namer et al, 1991;
Pujol et al, 1993; Fernö et al, 1994), also showing prognostic
power in node-negative patients (Spyratos et al, 1989; Tandon et
al, 1990; Granata et al, 1991). However, studies using immuno-
histochemistry to detect cath-D in carcinoma cells have provided
controversial results of cath-D as a prognostic factor in breast
cancer. The different results may be due to differences in patient
selection, follow-up times, antibodies or cut-off values (Ravdin,
1993; Cardiff, 1994; Rochefort, 1996; Westley and May, 1996).
Three reports describe an adverse prognostic value for the expres-
sion of cath-D in stromal cells but not in tumour cells (Tetû et al,
1993; Joensuu et al, 1995; O’Donoghue et al, 1995).
Urokinase plasminogen activator (uPA) is a serine protease,
which activates zymogen forms of other proteases like plasmin
and gelatinase A (also called MMP-2 or type IV collagenase) and
these both degrade type IV collagen (Liotta et al, 1981; Dano et al,
1985; Keski-Oja et al, 1992), one of the main constituents of the
basement membranes. Type 1 plasminogen activator inhibitor
(PAI-1) is a specific inhibitor of uPA and its expression is
enhanced in malignant breast tissue along with uPA as compared
with normal breast tissue (Foucré et al, 1991; Reilly et al, 1992;
Costantini et al, 1996). Several studies have demonstrated that
increasing amounts or activity of uPA and PAI-1 are associated
with aggressive growth properties and worse prognosis in breast
cancer. These results have often been independent of other prog-
nostic factors leading to the suggestion that high levels of prote-
olytic enzymes indicate a more aggressive disease within a defined
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Summary Cytosolic determinations of cathepsin-D (cath-D), urokinase plasminogen activator (uPA) and its specific inhibitor PAI-1 have
shown an association with adverse prognosis in breast cancer. Our aim was to study the distribution of these markers in small axillary node-
negative breast carcinomas using immunohistochemistry and relate the semiquantitative results to known prognostic factors, the expression
of tenascin-C (Tn-C) in invasion border of the tumour and prognosis. All the 158 women (159 tumours) were treated with breast conserving
surgery and postoperative radiotherapy. Cytoplasmic immunoreactivity for cath-D was seen in carcinoma cells in 47% and in stromal cells in
44%. Nearly all tumours expressed uPA and PAI-1, which were categorized to cytoplasmic expression in carcinoma cells and diffuse stromal
expression and quantified – / + / ++ / +++ and further dichotomized for purposes of analysis. Expression of uPA and PAI-1 in stromal
fibroblasts was recorded as – / +. Cytoplasmic and stromal cell cath-D contents were associated with grade, proliferation, Tn-C expression in
the tumour invasion border and the development of distant metastasis. In multivariate analysis stromal cath-D proved to be an independent
prognostic factor for metastasis. Stromal expression of uPA was associated with an increased risk of local recurrence; otherwise high levels
of uPA did not associate with other prognostic factors nor with prognosis. Fibroblastic expression of PAI-1 showed an association with both
local and distant disease recurrence. However, no consistent association between the immunohistochemically quantified uPA and PAI-1 and
prognosis was found. In conclusion, immunohistochemical determination of cath-D seems to be a viable method to predict a higher risk of
metastasis but not local recurrence in small axillary node-negative breast carcinomas.
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adjuvant therapies (Duffy et al, 1988; Jänicke et al, 1989, 1993;
Foekens et al, 1992, 1994; Spyratos et al, 1992; Grondal-Hansen
et al, 1993, 1997; Bouchet et al, 1994). High contents of uPA and
PAI-1 in renal carcinoma tissue appear to be strong and indepen-
dent prognostic factors (Hofmann et al, 1996). The high-grade
immunohistochemical uPA staining of epithelial cells in Dukes’ B
colorectal cancer has also been discovered to be of prognostic
value (Mulcahy et al, 1994).
Immunohistochemistry uses only one 4–6 mm slice of formalin-
fixed tissue for each analysis and saves tissue for other diagnostic
and prognostic studies. This is a clear advantage in small tumours.
Our purpose was to study the distribution and level of the
immunoreactivities for cath-D, u-PA and PAI-1 and their possible
prognostic value to predict local or distant recurrence in axillary
node-negative small breast carcinomas all treated with breast
saving surgery. The archival material has been characterized
earlier and several prognostic factors have been evaluated. The
previously studied prognostic factors include tumour size,
histology, grade, possible intraductal component (DCIS), ploidy,
proliferation measured with S phase fraction (SPF) and Ki-67
antigen expression, erbB-2 oncoprotein, p53 protein and tenascin-
C (Tn-C) expression (Jahkola et al, 1998). The expression of the
extracellular matrix glycoprotein Tn-C in the invasion border of
these very same tumours is a prognostic factor for both local recur-
rence after breast saving surgery and distant metastasis (Jahkola et
al, 1998). The prognostic significances of cath-D, uPA and PAI-1
immunoreactivities, and their relationships with other prognostic
factors, are analysed here.
PATIENTS AND METHODS
Patients
All patients included in this study had undergone breast saving
surgery and post-operative radiotherapy (25 ´ 2 Gy) but no
adjuvant hormonal- or chemotherapy for axillary node-negative
invasive breast carcinoma. The patients and histopathological
characteristics of the tumours have been described in detail earlier
(Jahkola et al, 1998). In short, the original patient group of 143
women (144 tumours, one bilateral) was followed for a median of
7.8 years (range 5.4–11.4 years) during which seven local recur-
rences (5%) and 14 distant metastases (10%) were diagnosed four
patients having both. Due to the small number of recurrences a new
additional patient group was included to strengthen the statistical
power of the study. This additional group consisted of 15 women
with a recurrent disease (seven local recurrences and 11 distant
metastases three having both) selected from a patient population
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Figures 1–4 Positive immunoreactivity for cathepsin-D in carcinoma cells (Figure 1) and in stromal cells (Figure 2) in ductal breast carcinomas. Positive
immunoreactivity for uPA (Figure 3) and PAI-1 (Figure 4) in the cytoplasm of lobular breast carcinoma
1 2
34with similar treatment for node-negative breast carcinoma and
equal recurrence rates as the original patient group (Jahkola et al,
1998).
Immunohistochemical analysis of cath-D, uPA and PAI-1
Formalin-fixed and paraffin-embedded tumour samples were cut
to 4-mm-thick sections, deparaffinized and endogenous peroxidase
was blocked for 30 min in 0.3% hydrogen peroxide in methanol.
Alkaline phosphatase anti-alkaline phosphatase (APAAP kit
system 40, cat. no. K0670, DAKO A/S, Denmark) and strepta-
vidin–peroxidase (StreptAB complex/HRP kit, cat. no. K492,
DAKO A/S, Denmark) methods were applied according to the
manufacturer’s instructions. 3-Amino-9-ethyl carbazole was used
as chromogen for peroxidase, Mayer’s haematoxylin was used for
nuclear staining and the sections were mounted with Aquamount
(BDH Ltd, Poole, UK). Mouse monoclonal antibodies against
cath-D (clone 1C11, Triton Diagnostics, Alameda, CA, USA), uPA
(cat. No 3689, American Diagnostica Inc., Greenwich, CT, USA)
and PAI-1 (cat. No. 3785, American Diagnostica Inc., Greenwich,
CT, USA) were applied at dilutions of 1:20 (0.13 mg ml-1, 1 h at
room temperature), 1:75 (13 mg ml-1, 1 h at 37°C) and 1:100
(10 mg ml-1, 1 h at 37°C) respectively. For cath-D, liver sections
were used as positive controls, and for uPA and PAI-1, positive
controls were breast carcinoma specimens known to stain for the
markers. Negative controls consisted of incubations with omission
of primary antibodies.
All tumours were evaluated for cath-D, uPA and PAI-1 expres-
sion by a pathologist unaware of the outcome of patients. A few
samples in each set of immunohistochemistry could not be inter-
preted due to technical failures or lack of carcinoma tissue.
The expression of cath-D was typically granular and confined to
cytoplasm of carcinoma cells, but also of stromal macrophages
and fibroblasts. We noticed no preference of location of cath-D-
positive cells between central parts and periphery of the tumours.
The scoring of cytoplasmic cath-D immunoreactivity was assessed
according to Isola et al (1993): tumours with a clearly detectable
level of 10% or more of strongly positive carcinoma cells were
defined as positive for cytoplasmic reactivity. When 10% or more
of stromal cells were strongly positive, the stromal expression was
called positive respectively (Tetû et al, 1993) (Figures 1 and 2).
Immunoreactivity for uPA and PAI-1 were seen in a vast
majority of tumours. Expression was seen in the cytoplasm of
carcinoma cells (Figures 3 and 4) and diffusely in the surrounding
stroma, but also frequently in the cytoplasm of benign breast
epithelia and stroma (not shown). For uPA and PAI-1, the classifi-
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Table 1 Associations between cath-D, uPA and PAI-1 in their different areas of expression in small axillary node-negative breast carcinomas
All Cytoplasmic Stromal cell Cytoplasmic Stromal Fibroblastic Cytoplasmic Stromal Fibroblastic
tumours cath-D cath-D uPA high uPA high uPA PAI-1 high PAI-1 high PAI-1
positive (%) positive (%) grade (%) grade (%) positive (%) grade (%) grade (%) positive (%)
All tumours 159 73 (47) 68 (44) 96 (63) 70 (46) 44 (29) 60 (40) 50 (33) 47 (31)
Cytoplasmic
cath-D+ 73 –
cath-D– 82 –
Stromal cell
cath-D+ 68 43 (63) –
cath-D– 87 30 (34) –
P = 0.0004***
Cytoplasmic
uPA high grade 96 47 (49) 46 (48) –
uPA low grade 57 24 (44) 18 (33) –
P = 0.5 P = 0.06
Stromal
uPA high grade 70 28 (41) 26 (38) 47 (67) –
uPA low grade 83 43 (53) 38 (47) 49 (59) –
P = 0.1 P = 0.3 P = 0.3
Fibroblastic
uPA+ 44 21 (48) 27 (61) 38 (86) 25 (57) –
uPA– 109 50 (47) 37 (35) 58 (53) 45 (41) –
P = 0.9 P = 0.003* P < 0.0001*** P = 0.08
Cytoplasmic
PAI-1 high grade 60 32 (54) 25 (42) 45 (76) 24 (41) 18 (31) –
PAI-1 low grade 91 38 (43) 39 (44) 48 (53) 45 (50) 26 (29) –
P = 0.2 P = 0.9 P = 0.005** P = 0.3 P = 0.8
Stromal
PAI-1 high grade 50 27 (55) 18 (37) 27 (54) 27 (54) 16 (32) 28 (56) –
PAI-1 low grade 101 41 (43) 45 (47) 66 (68) 42 (42) 28 (28) 32 (32) –
P = 0.2 P = 0.2 P = 0.09 P = 0.2 P = 0.6 P = 0.004*
Fibroblastic
PAI-1+ 47 27 (57) 29 (62) 43 (93) 15 (33) 22 (48) 26 (55) 14 (30) –
PAI-1– 104 43 (43) 35 (35) 50 (49) 54 (52) 22 (21) 34 (33) 36 (35) –
P = 0.09 P = 0.002** P < 0.0001*** P = 0.03* P = 0.001*** P = 0.01* P = 0.6 –cation of cytoplasmic and diffuse stromal immunoreactivities was
performed visually taking into account both intensity and the
proportion of cells or area of the tumour stained. The categories
were negative (–), slightly (+), moderately (++), or strongly, posi-
tive (+++). In some samples the stromal fibroblasts showed a
moderate to strong intensity, which phenomenon seemed indepen-
dent of the diffuse stromal immunoreactivity and this was
recorded separately (–/+). For purposes of analysis the categories
of cytoplasmic and diffuse stromal uPA and PAI-1 reactions were
combined to form a low-grade and a high-grade group for both
cytoplasmic and diffuse stromal staining of uPA and PAI-1 (see
Results for distribution).
Statistical methods
Chi-square test, Fisher’s exact test and Mann–Whitney U-test were
used to test for association between variables. The statistical signif-
icance of differences in outcome between patients with or without a
prognostic factor was calculated using the Cox proportional hazard
model to compute the hazard ratios (HR) of disease recurrence. The
statistical significance of the effect of the continuous variables on
disease recurrence was also tested with the Cox proportional hazard
model with the variable to be tested as the only covariate. The
multivariate analysis for metastasis was performed with the Cox
proportional hazard model entering the variables significant in the
univariate analysis. All the tests were two-sided and P-values
smaller than 0.05 were considered significant.
RESULTS
The distribution of immunoreactivity
In 155 out of 159 tumours cath-D expression could be interpreted.
There were 73 tumours (47%) showing immunoreactivity for cyto-
plasmic cath-D and 68 tumours (44%) for stromal cell expression.
Cross-tabulation of cytoplasmic and stromal cell cath-D reactivi-
ties showed an association (P = 0.0004) with 43 tumours (28%)
expressing both (Table 1).
Staining for uPA could be interpreted in 153 tumours and PAI-1
in 151 tumours. Cytoplasmic uPA was missing in nine tumours
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Table 2 Associations of cath-D, uPA and PAI-1 with histopathological and prognostic factors in small axillary node-negative breast carcinomas
All Cytoplasmic Stromal cell Cytoplasmic Stromal Fibroblastic Cytoplasmic Stromal Fibroblastic
tumours cath-D cath-D uPA high uPA high uPA PAI-1 high PAI-1 high PAI-1
positive (%) positive (%) grade (%) grade (%) positive (%) grade (%) grade (%) positive (%)
All tumours 159 73 (47) 68 (44) 96 (63) 70 (46) 44 (29) 60 (40) 50 (33) 47 (31)
Histology
Ductal 95 47 (51) 44 (47) 54 (59) 40 (44) 28 (29) 35 (38) 36 (40) 33 (35)
Lobular 35 16 (47) 12 (35) 24 (67) 17 (49) 7 (20) 17 (49) 9 (26) 9 (26)
Othersa 29 10 (36) 12 (43) 18 (67) 13 (48) 9 (31) 8 (33) 5 (22) 5 (17)
P = 0.4 P = 0.5 P = 0.6 P = 0.9 P = 0.5 P = 0.4 P = 0.1 P = 0.2
Gradeb
1 51 12 (24) 20 (40) 28 (61) 19 (41) 14 (27) 14 (30) 20 (43) 12 (24)
2 34 21 (62) 12 (35) 22 (67) 15 (45) 10 (29) 15 (45) 11 (34) 14 (41)
3 26 16 (67) 17 (71) 12 (46) 13 (50) 9 (35) 9 (35) 9 (34) 9 (35)
P = 0.0002*** P = 0.02* P = 0.3 P = 0.8 P = 0.8 P = 0.4 P = 0.6 P = 0.2
DCIS+c 57 28 (50) 25 (47) 32 (58) 27 (49) 14 (25) 19 (35) 26 (48) 15 (26)
DCIS– 102 45 (45) 43 (43) 64 (65) 43 (44) 30 (29) 41 (43) 24 (25) 32 (31)
P = 0.6 P = 0.9 P = 0.4 P = 0.5 P = 0.5 P = 0.3 P = 0.005** P = 0.5
EIC+d 12 8 (67) 6 (50) 6 (55) 6 (55) 2 (17) 5 (45) 4 (36) 3 (25)
EIC– 147 65 (45) 62 (43) 90 (63) 64 (45) 42 (29) 55 (39) 46 (34) 44 (30)
P = 0.2 P = 0.7 P = 0.6 P = 0.5 P = 0.4 P = 0.7 P = 0.9 P = 0.7
erbB-2+e 11 4 (36) 3 (27) 5 (45) 7 (64) 3 (27) 5 (45) 7 (64) 1 (9)
erbB-2– 131 58 (45) 54 (42) 80 (62) 55 (43) 37 (28) 52 (42) 37 (30) 35 (27)
P = 0.6 P = 0.3 P = 0.3 P = 0.2 P = 0.9 P = 0.8 P = 0.02* P = 0.2
p53 +f 22 13 (59) 13 (59) 11 (55) 9 (45) 7 (32) 4 (19) 6 (30) 8 (36)
p53 – 121 53 (45) 52 (44) 79 (68) 55 (47) 34 (28) 51 (44) 40 (35) 36 (30)
P = 0.2 P = 0.2 P = 0.3 P = 0.9 P = 0.7 P = 0.03*  P = 0.6 P = 0.5
Ki-67+g 80 45 (58) 48 (62) 52 (68) 32 (42) 28 (35) 29 (37) 29 (38) 28 (35)
Ki-67– 61 20 (33) 16 (26) 39 (67) 29 (50) 15 (25) 28 (49) 17 (30) 17 (28)
P = 0.003** P < 0.0001*** P = 0.97 P = 0.3 P = 0.18 P = 0.2 P = 0.4 P = 0.4
SPF highh 73 38 (53) 39 (54) 45 (64) 33 (47) 25 (35) 25 (35) 20 (29) 24 (33)
SPF low 72 28 (39) 22 (31) 42 (61) 28 (41) 15 (20) 28 (42) 22 (34) 20 (27)
P = 0.1 P = 0.005** P = 0.7 P = 0.4 P = 0.05* P = 0.4 P = 0.5 P = 0.4
Aneuploid 55 30 (55) 28 (51) 30 (57) 20 (38) 23 (42) 23 (43) 25 (47) 19 (35)
Diploid 95 39 (42) 37 (40) 60 (66) 44 (48) 18 (19) 32 (36) 21 (24) 25 (26)
P = 0.1 P = 0.2 P = 0.3 P = 0.2 P = 0.003** P = 0.4 P = 0.006** P = 0.3
aothers: two papillary, one medullary, two mucinous, 14 tubular, ten tubulolobular; bgrade of 111 ductal and tubular carcinomas; cDCIS = intraductal component;
dEIC = extensive intraductal component; eerbB-2 stained only of the original patient material of 143; fp53 cut-off 20% of nuclei positive; gKi-67 cut-off 5% of
nuclei positive; hSPF cut-offs: median SPF of diploid tumours 2.4% and median of aneuploid tumours 8.4%.(6%), + in 48 tumours (31%), ++ in 73 tumours (48%) and +++ in
23 tumours (15%). For analyses groups, – and + were combined to
form a low-grade group of 57 tumours (37%), and ++ and +++ to
form a high-grade group of 96 tumours (63%). Stromal uPA was
noted in all tumours. In 83 (54%) it was weak and this was called
low-grade in the analyses. Moderate expression was seen in 59
tumours (39%) and strong in 11 tumours (7%) and these were
combined to one high-grade stromal uPA group of 70 tumours
(46%).
Cytoplasmic PAI-1 was expressed in all tumours. In 19 (12%) it
was weak, in 72 (48%) moderate and in 60 (40%) strong. For
analyses, groups + and ++ were combined to present a low-grade
cytoplasmic PAI-1 group of 90 tumours (60%). Stromal PAI-1 was
missing in 21 tumours (13%), + in 80 tumours (53%), ++ in 48
tumours (32%) and +++ in two tumours (1%). For analyses, – and
+ were combined to one low-grade stromal PAI-1 group of 101
tumours (67%), and ++ and +++ to a high-grade group of 50
tumours (33%).
Relations within proteolytic enzymes
High levels of stromal cell cath-D was associated with cytoplasmic
cath-D and expression of uPA and PAI-1 in fibroblasts, but not
with cytoplasmic or diffuse stromal expressions of uPA and PAI-1.
Generally the cytoplasmic expression of uPA and PAI-1 associated
with each other and with fibroblastic expressions. The diffuse
stromal uPA associated only with fibroblastic PAI-1. The stromal
content of PAI-1 showed an association with cytoplasmic and
fibroblastic PAI-1, but not with uPA or cath-D (Table 1).
Relations with other prognostic factors
Tumour size, histology, grade according to Bloom and Richardson,
the immunohistochemical detection of erbB-2 oncoprotein, p53
protein and Ki-67 antigen, as well as the flow-cytometric measure-
ment of ploidy and SPF have been performed and presented earlier
(Jahkola et al, 1998). There were no significant differences in the
distributions of cath-D, uPA and PAI-1 with respect to patient age
or tumour size (data not shown).
Cytoplasmic cath-D expression was associated with grade
(P = 0.0002) and proliferation measured with Ki-67 (P = 0.003)
(Table 2). Cath-D expression in stromal cells was associated also
with grade (P = 0.02) and proliferation (P < 0.0001 for Ki-67 and
P = 0.005 for SPF) (Table 2, cut-offs in footnotes).
There was no association between stromal or cytoplasmic uPA
and other prognostic factors listed in Table 2. Fibroblastic uPA
showed an association with high SPF (P = 0.05) and aneuploidy
(P = 0.003) (Table 2).
Cytoplasmic PAI-1 associated with low or missing p53 expres-
sion (P = 0.02). Stromal expression of PAI-1 was associated with
intraductal component (DCIS) (P = 0.005), erbB-2 (P = 0.02) and
aneuploidy (P = 0.006), whereas fibroblastic PAI-1 expression did
not show association with any of the listed prognostic factors
(Table 2).
Relations with the expression of Tn-C in invasion
border
An invasion border could be identified in 121 out of the 159
tumours in the available archival specimens. The expression of
Tn-C at the invasive front of these tumours was shown earlier to
correlate to higher risk of distant metastasis (Jahkola et al, 1996,
1998a) and local recurrence after breast-conserving surgery
(Jahkola et al, 1998a). A Tn-C-positive invasion border was asso-
ciated with cath-D expression both in carcinoma and stromal cells.
There was also an association between Tn-C and fibroblastic PAI-
1 (Table 3).
Univariate analysis for distant and local recurrence
In univariate analysis for metastasis, cytoplasmic cath-D (HR =
3.80, confidence intervals (CI) = 1.50–9.57, P = 0.005), stromal
cell cath-D (HR = 4.28, CI = 1.70–10.78, P = 0.002) and fibro-
blastic PAI-1 (HR = 2.44, CI = 1.06–5.61, P = 0.04) were signifi-
cant prognostic factors. Our immunohistochemical quantification
failed to show any association between uPA and metastasis. For
local recurrence, only stromal uPA (HR = 7.24, CI = 1.62–32.34,
P = 0.01) and fibroblastic PAI-1 (HR = 4.3, CI = 1.44–12.85,
P = 0.009) showed prognostic power (Table 4).
The previously shown prognostic factors for metastasis are size
(HR = 2.56, CI = 1.13–5.94, P = 0.02), SPF of diploid tumours
(HR = 3.16, CI = 1.02–9.81, P = 0.05), Ki-67 (HR = 5.5, CI =
1.6–18.7, P = 0.006) and Tn-C in the invasion border (HR = 3.4,
CI = 1.1–10.4, P = 0.03). For local recurrence only Tn-C in the
invasion border was significant in predicting local recurrence (HR
= 11.0, CI = 1.4–85.1, P = 0.02).
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Table 3 Association of tenascin-C expression in invasion border with
cytoplasmic and stromal expression of cath-D, uPA and PAI-1 in axillary
node-negative breast carcinomas
All tumours Tn-C positive Chi-square
invasion border (%) P-value
All 121 63 (52)
Cytoplasmic
cath-D+ 53 33 (62) 0.05
cath-D– 66 29 (44)
Stromal cell
cath-D+ 54 34 (63) 0.03
cath-D– 65 28 (43)
Cytoplasmic
uPA high grade 75 43 (57) 0.3
uPA … low grade 41 19 (46)
Stromal
uPA … high grade 54 31 (57) 0.3
uPA … low grade 65 31 (48)
Fibroblastic
uPA+ 39 24 (62) 0.15
uPA– 82 39 (48)
Cytoplasmic
PAI-1 high grade 45 22 (48) 0.5
PAI-1 … low grade 69 40 (55)
Stromal
PAI-1 high grade 35 21 (60) 0.3
PAI-1 low grade 84 41 (49)
Fibroblastic
PAI-1+ 42 27 (64) 0.05
PAI-1– 79 36 (46)
An invasion border was present in 121 tumours out of the 159 in the archival
specimens available. Cath-D cut-off 10% of cells strongly positive, for cut-offs
of uPA and PAI-1 see text.Multivariate analysis for metastasis and local
recurrence
When cytoplasmic and stromal cath-D and fibroblastic PAI-1 were
introduced into the multivariate analysis, stromal cell cath-D
remained the strongest prognostic factor for metastasis (Table 5).
After adding the previously found prognostic factors for metas-
tasis, Ki-67, Tn-C in the invasion border and tumour size, each at a
time, Ki-67 remained as the strongest prognostic factor followed
by stromal cath-D, Tn-C, cytoplasmic cath-D, fibroblastic PAI-1
and tumour size as the weakest (data not shown).
Both fibroblastic PAI-1 and stromal uPA remained statistically
significant in the multivariate analysis for local recurrence (Table
6). When the previously studied Tn-C in invasion border was
included, it turned out to be the weakest of these three (data not
shown).
DISCUSSION
This study showed a significant prognostic value for cath-D
expression in carcinoma cells, but also in stromal cells, to predict a
higher risk of distant metastasis. In the study of Henry et al (1990),
cath-D expression in malignant epithelial cells was unexpectedly
protective of disease recurrence in axillary node-positive patients
whereas several other studies have not proven a statistically
significant relation between cath-D expression and prognosis
(Domagala et al, 1992; Kandalaft et al, 1993; Winstanley et al,
1993; Armas et al, 1994; Castiglioni et al, 1994; Ravdin et al,
1994; Alo et al, 1996). Using the same monoclonal antibody as in
the present study, Isola et al (1993) found that the expression of
cath-D in tumour cells was an independent and strong indicator of
adverse prognosis in axillary node-negative patients (n = 262).
Another study correlated an intense cath-D immunostaining with
worse prognosis in node-positive (n = 76) but not in node-negative
(n = 66) patients (Aaltonen et al, 1995).
Three reports describe a statistically significant adverse prog-
nostic value for the expression of cath-D in stromal cells but not
tumour cells (Tetû et al, 1993; Joensuu et al, 1995; O’Donoghue et
al, 1995). Tetû et al (1993) studied only axillary node-positive
patients, and in the studies of Joensuu et al (1995) and
O’Donoghue et al (1995) the number of axillary node-negative
patients was relatively low (53 and 61 respectively). The cytosolic
cath-D content has been correlated to carcinoma cells (Roger et al,
1994) and to stromal macrophages (Razumovic et al, 1997)
suggesting that the cytosolic cath-D is the cumulative result of
cath-D content in both carcinoma cells and stromal cells.
Considering that the cytosolic studies have provided lots of
evidence of the prognostic usefulness of cath-D in breast cancer,
we conclude that cytoplasmic and stromal cath-D immunoreac-
tivity can be used either alone or combined to predict the risk of
systemic metastasis in early breast carcinoma patients. This is in
accordance with the recent meta-analysis result of a relationship
between high cath-D values and poor disease-free survival in
node-negative breast cancer patients (Ferrandina et al, 1997).
The associations of cath-D with grade and proliferation have
been reported earlier by others (Charpin et al, 1993; Joensuu et al,
1995). Unlike us, Isola et al found no association between cyto-
plasmic cath-D and grade (Isola et al, 1993). Stromal cell cath-D
has been shown to scatter to the invasive area of the tumour
(O’Donoghue et al, 1995). We did not notice this in the small
tumours of our study. Instead, we found a significant correlation
between both cytoplasmic and stromal cell content of cath-D and
the expression of Tn-C in the invasion border that we suggest is
related to invasion (Jahkola et al, 1998b).
Concerning uPA and PAI-1, our aim was to quantify immuno-
histochemically their contents in small node-negative breast carci-
nomas and relate the results to prognosis. We found a correlation
between fibroblastic PAI-1 and both local and distant recurrence,
and between diffuse stromal uPA and local recurrence. There were
also correlations between cytoplasmic and fibroblastic expression of
uPA and PAI-1, indicating perhaps a general increase in proteolytic
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Table 4 Hazard ratios (HR) for local recurrence and metastasis in 158
women with 159 axillary node-negative breast carcinomas treated with
breast-saving surgery and post-operative radiotherapy
HR for local HR for
recurrence P-value metastasis P-value
Cytoplasmic
cath-D+ 1.63 0.37 3.8 0.005
cath-D– 1.0 1.0
Stromal
cath-D+ 2.4 0.12 4.28 0.002
cath-D– 1.0 1.0
Cytoplasmic
uPA high grade 2.22 0.22 1.51 0.37
uPA low grade 1.0 1.0
Stromal
uPA high grade 7.24 0.01 1.03 0.94
uPA low grade 1.0 1.0
Fibroblastic
uPA+ 1.01 0.92 0.88 0.88
uPA– 1.0 1.0
Cytoplasmic
PAI-1 high grade 0.62 0.42 1.23 0.62
PAI-1 low grade 1.0 1.0
Stromal
PAI-1 high grade 0.82 0.74 1.08 0.86
PAI-1 low grade 1.0 1.0
Fibroblastic
PAI-1+ 4.31 0.009 2.44 0.04
PAI-1– 1.0 1.0
Cath-D cut-off 10% of cells strongly positive, for cut-offs of uPA and PAI-1
see text.
Table 5 Multivariate analysis (Cox proportional hazard model) of the three
covariates statistically significant in univariate analysis of metastasis
Covariate P HR CI (95%)
Cytoplasmic cath-D 0.068 2.46 0.94–6.45
Stromal cell cath-D 0.034 2.88 1.08–7.71
Fibroblastic PAI-1 0.24 1.66 0.71–3.89
Table 6 Multivariate analysis (Cox proportional hazard model) of the two
covariates statistically significant in univariate analysis of local recurrence
Covariate P HR CI (95%)
Diffuse stromal uPA 0.001 8.06 2.64–24.65
Fibroblastic PAI-1 0.0003 12.67 2.76–58.12activity in carcinomas. This has previously been suggested in studies
comparing the immunohistochemical expressions of uPA and PAI-1
in normal breast epithelia, in benign tumours and in carcinomas
(Reilly et al, 1992; Bianchi et al, 1995; Christensen et al, 1996;
Costantini et al, 1996). Christensen et al (1996) have described
fibroblastic uPA and PAI-1 staining in a subgroup of poorly differ-
entiated tumours which is in accordance with our result of a connec-
tion between fibroblastic PAI-1 and worse prognosis.
We failed to observe a consistent correlation between increased
immunohistochemical levels of uPA and PAI-1 and prognosis.
This may be due to the nearly ubiquitous expression of these
components in normal breast tissue and difficulties in quantifica-
tion thereof. Immunohistochemistry can only be semiquantitative,
though anatomically accurate, and it seems that it cannot replace
cytosolic measurements of uPA and PAI-1 for prognostic
purposes. The immunohistochemical analysis for urokinase plas-
minogen activator receptor (uPAR) may be more useful since its
presence is required for assembling an active uPA system at the
surface of the cell, whereas the expression of uPA and PAI-1 at a
certain localization may be either the site of production or the site
of activity (Christensen et al, 1996).
In conclusion, our results show that the immunohistochemical
analysis for cath-D in the cytoplasm of both carcinoma cells and
stromal cells was related to increased risk of distant metastasis but
not of local recurrence after breast-conserving surgery. In multi-
variate setting the expression in stromal cells was the strongest
prognostic factor for metastasis. Cath-D immunoreactivity was
associated with grade and proliferation as well as with the expres-
sion of Tn-C in tumour invasion border. We failed to produce a
consistent immunohistochemical quantification of uPA and PAI-1
for prognostic purposes. Fibroblastic PAI-1 expression associated
with both local recurrence and distant metastasis, and diffuse
stromal uPA associated with local recurrence. These studies have to
be repeated in the future before definitive conclusions can be drawn.
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